Phenotypic presentation of family members of ATTRv probands and subsequent disease penetrance

Luca Fazzini; Matteo Castrichini; Yan Li; Jose De Melo; Marta Figueiral; Jenny J. Cao; Eric W. Klee; Christian Cadeddu Dessalvi; Martha Grogan; Angela Dispenzieri; Naveen L. Pereira

doi:10.1101/2024.09.06.24313219

Abstract

BACKGROUND Hereditary transthyretin amyloid cardiomyopathy (ATTRv-CM) is being increasingly diagnosed due to enhanced awareness and availability of newer therapeutics. Multiple TTR variants have been described worldwide, but with uncertain disease penetrance. The characteristics and outcomes of “previously undiagnosed” pathogenic-likely pathogenic (P/LP) TTR variant (genotype or G+; cardiac phenotype or P-) carriers are unknown which has important prognostic and therapeutic implications, especially for affected family members. This descriptive study aimed to delineate phenotype and cardiac penetrance in “previously undiagnosed” G+P-family members of ATTRv probands.

METHODS Demographic, electrocardiographic (ECG), genetic, and imaging (echocardiography, cardiac technetium-99m pyrophosphate (PYP) and magnetic resonance imaging) data were analyzed. The prediction effect of selected baseline characteristics for ATTRv-CM development was evaluated. Kaplan-Meier and Cox regression methods were used to describe risk and predictors of ATTRv-CM development in family members.

RESULTS There were 85 G+P-family members identified. Mean age was 48.5±11.7 years, 39% were male, 18% had a diagnosis of peripheral neuropathy, 15% with a history of carpal tunnel syndrome, and 4% had atrioventricular block at baseline. Of these, 55 patients had follow-up imaging studies. After a median 6.8-year follow-up, 22% developed ATTR-CM with a 10-year estimated risk of 29.5% (95% CI 7.9-46.0). Cardiac penetrance increased with increasing family member’s age. Proband’s diagnosis age (p=0.0096) and artificial intelligence (AI)-ECG prediction (p=0.0091) were promising baseline predictors of time to ATTRv-CM development.

CONCLUSION In previously undiagnosed G+P-ATTRv family members, the incidence of subsequent CM is high. Predictors for CM development such as proband’s diagnosis age and AI-determined ECG probability of ATTR-CM require further investigation.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Dr. Luca Fazzini received a grant funded by the Italian Society of Cardiology and Bruno Farmaceutici during the research fellowship at Mayo Clinic, Rochester.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The institutional review board of the Mayo Clinic Foundation approved this study which was a single-center, observational, and retrospective study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes